ASH Issues Recommendations to Improve FDA’s Guidance on NGS-based Tests for Germline Diseases
ASH submitted comments to the Food and Drug Administration (FDA) supporting the Agency’s draft guidance for Next Generation Sequencing (NGS)-based tests for germline diseases. ASH’s comments ask for clarification and make additional recommendations for important aspects worth including in the final guidance so that NGS-based tests can be effectively designed, developed and validated for various hematologic diseases. The Society’s suggestions call for the FDA to: 1) clarify its review and approval of NGS-based tests for germline diseases; 2) include in the final guidance its regulation of other types of NGS-based tests (i.e., tumor genome sequencing) that are valuable for the identification of structural genetic alterations; 3) address variant interpretation and 4) develop a complimentary guidance for somatic diseases. ASH’s recommendations were developed with input from various committee members and built on the Society’s previous comments to the Agency on this topic.
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission